Please select the option that best describes you:
Do you offer adjuvant osimertinib to EGFR exon 19 deleted patients with T2N0 NSCLC treated with definitive SBRT?
I.e. based on the findings of ADAURA in surgically managed patients.
Answer from: Radiation Oncologist at Academic Institution
Given the fairly striking benefit of ADAURA in resected patients, there likely would be a locoregional and distant control and likely survival benefit to this approach but we don't have data to support this. PACIFIC-4 is currently enrolling. Study of durvalumab vs placebo in patients with early stag...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
Recent press release data (presumably to be presented at an upcoming meeting) states that there is a survival benefit for adjuvant osimertinib in the ADAURA study. That said, I do not offer adjuvant osimertinib to EGFR exon 19 deleted patients with T2N0 disease following SBRT. This certainly warrant...